Nov 13, 2025 09:35AM BTIG Downgrades Mersana (MRSN) to Neutral

Nov 13, 2025 07:47AM Wedbush Downgrades Mersana (MRSN) to Neutral

Aug 14, 2025 11:08AM Mersana (MRSN) PT Lowered to $36 at Truist; All Eyes on 2H25 Update

Aug 14, 2025 06:57AM Mersana (MRSN) PT Lowered to $30 at Guggenheim

Aug 13, 2025 12:59PM Mersana (MRSN) PT Raised to $17 at BTIG

Aug 13, 2025 07:05AM Mersana Therapeutics (MRSN) Misses Q2 EPS by $4.71

Jun 2, 2025 08:10AM Mersana Therapeutics (MRSN) Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting

May 15, 2025 03:15PM Mersana (MRSN) PT Raised to $10 at Truist Securities

May 15, 2025 07:08AM Mersana Therapeutics (MRSN) Reports In-Line Q1 EPS

May 6, 2025 07:02AM Mersana Therapeutics (MRSN) Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer

Mar 3, 2025 07:06AM Mersana Therapeutics (MRSN) Tops Q4 EPS by 4c

Feb 6, 2025 05:10AM William Blair Starts Mersana (MRSN) at Outperform

Nov 15, 2024 04:52AM Citi Starts Mersana (MRSN) at Buy

Nov 13, 2024 07:06AM Mersana Therapeutics (MRSN) Misses Q3 EPS by 18c

Aug 14, 2024 06:27AM Mersana (MRSN) PT Lowered to $3 at Baird

Aug 13, 2024 07:02AM Mersana Therapeutics (MRSN) Misses Q2 EPS by 3c